Prothena Corp. (PRTA) Issues Encouraging Update on NEOD001 Phase 1/2 in AL Amyloidosis; Results Support Phase 3
Tweet Send to a Friend
Prothena Corp. (NASDAQ: PRTA) announced new clinical data from the multiple ascending dose portion of its ongoing Phase 1/2 trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
